BRCA1 and cancer: The synthetic lethality observed between BRCA1/2 mutations and poly(ADP-ribose) polymerase (PARP) inhibition exemplifies how DDR-targeted therapies can selectively kill cancer cells with homologous recombination deficiencies while sparing normal tissues [16,17].